EDG 7500
Alternative Names: EDG-7500Latest Information Update: 30 Jun 2025
At a glance
- Originator Edgewise Therapeutics
- Class Cardiovascular therapies; Heart failure therapies; Small molecules
- Mechanism of Action Sarcomere modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypertrophic cardiomyopathy
- Phase I Kidney disorders
- Preclinical Cardiovascular disorders
Most Recent Events
- 24 Jun 2025 Phase-I clinical trials in Kidney disorders (In volunteers) in USA (PO) (NCT07034768)
- 28 May 2025 Pharmacokinetics and adverse event data from a phase I pharmacokinetics trial presented at the 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)
- 03 Apr 2025 Efficacy and adverse events data from a phase II CIRRUS-HCM in Hypertrophic cardiomyopathy released by Edgewise Therapeutics